BICX102

**BICX102** is a biodegradable, sustained-release subcutaneous implant formulation of **naltrexone**, an opioid antagonist developed by **BioCorRx** for treating **opioid use disorder** and **alcohol use disorder**. It delivers naltrexone via a solid depot pellet implanted into fatty tissue through a minimal procedure, aiming to reduce cravings over an extended period and provide a non-addictive alternative to oral therapies. The FDA has accepted the 505(b)(2) pathway for approval, supported by a $5.6 million NIH/NIDA grant, with BioCorRx submitting a Pre-IND package.[1][3][5][9][11][13]

Other names

BICX104BICX-104BICX 104